ABCL AbCellera Biologics Inc

$ABCL $GANX $COYA This is forced liquidation for a lot of mutual funds who have their fiscal year end today. It’s the second most ETF selling in history of the ETFs

$ABCL The news: Over the past ~3 weeks—from late September to mid-October—AbCellera has seen a wave of senior-level hiring. The key lies in the specific roles: Head of Quality Assurance, Director/Senior Director of QC, Director of QA Validation, Head of Process Development (CMC), and Head of CMC Portfolio Management. Layer by layer: A core QC team (June) → operations and translational science (July) → VP of Medical Affairs (September) → and now, senior leadership in Quality and CMC (October). Each step represents a move further up the value chain than the last. My take: A company doesn’t build out a full senior leadership layer for quality and manufacturing unless it anticipates having a product to manufacture and sell. Following the positive Phase 2 results this summer, the focus has shifted from mere hope to actual realization. The direction is clear—onward.

$ABCL This is starting to look like an amazing setup….. November 9th will be the catalyst to push us to 18 and up!

$ABCL Anybody besides me adding on this big old crazy bowl of fear trying to be generated here? I added twice ty.

$ABCL will Abcelera end up gobbled up like Metsera! Candidates: Lilly, PfizerAstra, Abbvie, Merck. Drug: antibody for reducing flushes post menopause and post hormonal treatment after breast cancer and after prostate cancer treatments. Premium: 200% Its the next blockbuster drug. Abceleras drug is more tolerable, a subcutaneous injection once every 3 months, very tolerable. OLE is going strong. Target: 35 acquisition, 65-100 USD long term. Acquirer will be tempted as Abcelera have a pipeline and a platform.

$ABCL Q3 earnings after market close. Focus on clinical updates for ABCL635, which has generated significant enthusiasm following breakthrough PH2 data in menopausal hot flashes. ABCL expects a loss of 17 cents per share on revenue of $6.21 million for the Q. While that would represent sequential improvement from the prior q’s loss of 18 cents/share, revenue of $4.1 million, it also reflects a y-o-y revenue decline of 31% as ABCL transitions from its antibody discovery platform business to a pipeline-focused biotech. Analysts rate the stock a Strong Buy,consensus PT of $17.17. Jefferies, UBS, JPMorgan initiated coverage in recent weeks with Buy ratings and price targets ranging from $17 to $21, all citing ABCL635’s commercial potential. The monthly subcutaneous antibody for vasomotor symptoms showed an 83% reduction in moderate-to-severe hot flashes versus 33% for placebo in PH2 results announced in AUG, prompting analysts to describe the efficacy as "unprecedented" and "best-in-class..."

$ABCL about to average up quite a bit come Monday, but this is actually just the beginning overall. Long term holder. We will look back at these prices. This is the biggest holding in my IRA account. Say what you want.

$ABCL now we need something in November and we are close to 20$ bwfore January. Long and strong 💪 Only problem i have with ABCL is i dont know if i ever gonna sell

$ABCL those of us that have been here for many years. Know the company doesn’t put out fluff, they are very strategic with their announcements, it gets rid of flippers and short timer such as yourself. We’ll see you back here when you help push us higher next time, until then take care 

$ABCL Looking forward to data/presentation in November. Look at this as opportunity, if you dont have your position. 84% is pretty significant to me.!!

$ABCL Lmao the day i post don't buy PM is the day we blast up, too funny! Anyway, welcome back $12S !!!

$ABCL I am just wondering who is selling in this area except the usual? Adding 5000 today between 10.8-11.20.

$ABCL 🚨👏👏👏👀 News Out 🗞️!!! 🔥 We are in BREAK-OUT Mode 👀 Chart 📈 Attached. WAVE 5 Price Target 🎯 $21 🔥!!! $ABCL One injection followed by 4 weeks later, 37.0% of patients had flushing completely disappear. Placebo: 2.2% 💉 - Patients with 90% or more reduction: 60.9% vs placebo 8.7% (Phase 2, 92 people, 600mg single dose) - Difference from placebo widened from 2.6 episodes/day (week 1) to 5.5 episodes/day (week 4) - 84% of patients responded &much/quite improved&; (placebo 27%) - 12 healthy postmenopausal women received 3 injections at 4-week intervals, and average liver values up to Phase 2 were similar to placebo. No gastrointestinal or liver abnormality signals - Half-life about 24 days, under development as monthly injection. Headache more frequent at 28.2% vs 13.0%, but mostly mild

$ABCL no one selling in volume at this price point. People know what this stock is worth!

$ABCL $ABCL If you're not already in it, perhaps a pilot position on a swing trade now. With an idea of The stock making a pretty good move into those two. Health care conferences. November 9: Q3 earnings and pipeline update. November 11: Stifel Healthcare Conference. November 16: Jefferies Global Healthcare Conference in London.

$ABCL just faded with the market thus far today on low volume. Buying opp in my opinion.

$ABCL Very low volume, moving on thin air right now! Shorts are definitely starting to feel the pain over the last several days, great start to the day! Sending positive vibes to the Fed chairman Mr. Warsh, please go easy on us today!

$ABCL 👀 $MRNA $PFE $LLY $SLS $ABCL The squeeze potential here is real imo. As of july 31 the stock had 23.6% of the float short and 9.7 days to cover. Probably since the company switched from service for fee to completely bet on themselves and people betting against the Q2 print. Latest insider buys • Aug 14: CFO Andrew Booth bought 37,200 shares at $10.32 (~$384K). • Aug 18: Director John Montalbano bought 10,000 shares at $11.03 (~$110K). • Aug 12: Hayden bought 46,387 shares at $10.37 (~$481K). No insider selling as of latest 6 months and good data readout so far as management tightens the burn rate per quarter. I’m betting the daily wedge plays out and put my money where my mouth is. Next objective will be breaking $12,86 and finally testing that $15 level imo. Once again I go all in! All in on management taking this home.

$ABCL ❤️ $REGN $PFE $MRNA $SLS $ABCL : 4 new Street initiations in 5 weeks 👀 Do people trade price targets? Goldman (Sep 24): Neutral, $13 JPMorgan (Sep 29): Overweight, $17 UBS (Oct 12): Buy, $18 Jefferies (Oct 30): Buy, $21 The big banks are showing up. On the chart I’m watching for a higher low ✅ done!! We about to attempt the $15 breakout. 👀😉 ABcellera 🔥 🔥 👀!!!

$ABCL Has been incredibly resilient in an abysmal market. Typically the type of stock worth owning when the market normalizes.